Our Pricing

Understanding the Wegovy Starting Dose: Complete UK Guide

The wegovy starting dose is a carefully calibrated 0.25mg weekly injection designed to minimise side effects whilst allowing your body to adapt to semaglutide [1]. Understanding the correct Wegovy starting dose protocol is essential for safe, effective weight loss treatment, with clinical trials demonstrating that proper dose escalation significantly reduces gastrointestinal side effects compared to higher initial doses [2]. At Cured Pharmacy, we provide transparent pricing from £69.00 for Wegovy, with full clinical support from our UK-registered prescribers throughout your titration journey.

What Is the Wegovy Starting Dose and Why Does It Matter?

The wegovy starting dose is precisely 0.25mg administered once weekly via subcutaneous injection for the first four weeks of treatment [1]. This carefully selected initial dose serves a critical physiological purpose: it allows your gastrointestinal system to gradually adapt to semaglutide's effects on gastric emptying and appetite regulation, significantly reducing the likelihood of nausea, vomiting, and other common side effects.

Clinical evidence from the STEP trials demonstrated that patients who followed the proper dose escalation schedule starting at 0.25mg experienced substantially fewer treatment discontinuations due to gastrointestinal adverse events compared to those who attempted higher initial doses [2]. The starting dose contains enough active semaglutide to begin modulating GLP-1 receptors in your brain and digestive system, initiating the weight loss process whilst your body builds tolerance.

It's essential to understand that the wegovy starting dose is not the therapeutic maintenance dose—it's the foundation of a structured five-month titration schedule designed by Novo Nordisk based on extensive clinical research. Rushing this process or skipping the 0.25mg starting phase increases your risk of intolerable side effects that may force treatment discontinuation before you reach the full 2.4mg maintenance dose where maximum weight loss benefits occur.

The Science Behind the Wegovy Starting Dose Protocol

Semaglutide works by mimicking the GLP-1 hormone that your body naturally produces after eating, binding to GLP-1 receptors in the brain's appetite centres and throughout the digestive tract [1]. The wegovy starting dose of 0.25mg provides sufficient receptor activation to begin therapeutic effects whilst allowing receptor upregulation to occur gradually over the first month, which is why this specific dose was selected through extensive dose-ranging studies during Wegovy's clinical development programme.

Complete Wegovy Starting Dose Titration Schedule

The full wegovy starting dose escalation follows a precise five-month protocol, with each dose level maintained for exactly four weeks before progression [3]. This schedule begins with the 0.25mg starting dose and systematically increases to reach the therapeutic maintenance dose of 2.4mg weekly.

Month 1 (Weeks 1-4): 0.25mg once weekly—this is your wegovy starting dose phase where your body begins adapting to semaglutide. Month 2 (Weeks 5-8): 0.5mg once weekly—the first dose increase, typically well-tolerated if the starting dose phase was completed. Month 3 (Weeks 9-12): 1.0mg once weekly—at this level, many patients begin experiencing more substantial appetite suppression. Month 4 (Weeks 13-16): 1.7mg once weekly—the penultimate dose before reaching maintenance. Month 5 onwards (Week 17+): 2.4mg once weekly—the full therapeutic maintenance dose used in STEP clinical trials [2].

Each four-week period at a given dose level serves a specific physiological purpose: it allows GLP-1 receptor density to adjust, permits your gastric emptying rate to stabilise at the new level of semaglutide activity, and ensures any transient side effects resolve before further dose escalation. Our clinical team at Cured Pharmacy monitors your progress throughout this titration, with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing all treatment protocols to ensure you receive appropriate support at each stage.

Wegovy Starting Dose Side Effects and Management

Even at the carefully calibrated wegovy starting dose of 0.25mg, some patients experience mild gastrointestinal side effects as their body adapts to semaglutide [4]. The most commonly reported side effects during the starting dose phase include mild nausea (affecting approximately 20% of patients), occasional bloating, and changes in bowel habits, though these are typically transient and resolve within the first two weeks.

Clinical trial data shows that side effects at the wegovy starting dose are significantly less severe than at higher doses, which is precisely why this gradual titration exists [2]. To minimise discomfort during your starting dose phase, our clinical team recommends several evidence-based strategies: eat smaller, more frequent meals rather than large portions; avoid high-fat foods which delay gastric emptying further; stay well-hydrated throughout the day; and administer your injection at a consistent time each week, preferably in the evening after eating.

If you experience persistent nausea or vomiting during the wegovy starting dose phase that doesn't improve after two weeks, contact our clinical team immediately rather than discontinuing treatment independently. In some cases, remaining at the 0.25mg starting dose for an additional four weeks before escalation can improve tolerance, and this decision should be made in consultation with your prescriber. Serious side effects such as severe abdominal pain, persistent vomiting, or signs of pancreatitis require immediate medical attention and treatment discontinuation.

When to Contact Your Prescriber During the Starting Dose

Whilst mild side effects during the wegovy starting dose phase are normal and expected, certain symptoms warrant immediate clinical review. Contact our team if you experience severe or persistent vomiting that prevents adequate hydration, severe abdominal pain particularly in the upper abdomen radiating to your back, visual changes, or symptoms of thyroid nodules such as a lump in your neck or persistent hoarseness [4]. Our UK-registered prescribers are available to assess whether dose adjustment or additional monitoring is required.

Wegovy Starting Dose Price and UK Availability at Cured Pharmacy

At Cured Pharmacy, the wegovy starting dose is available from £69.00, representing the cheapest UK price with complete transparency—no hidden fees, no surprise charges at checkout, and no inflated 'consultation fees' added after you've begun the assessment [5]. This upfront pricing includes your medication, free delivery via next-day courier in discreet packaging, and full clinical support from our UK-registered prescribers throughout your treatment journey.

The wegovy starting dose pen you receive contains four pre-filled 0.25mg doses, providing your complete first month of treatment in a single FlexTouch pen device. Unlike some pharmacies that charge separately for clinical consultations, medication, and delivery, our £69.00 price covers everything required to begin your Wegovy treatment safely and legally under UK regulations. New patients can save an additional £20 off their first order using code Weightlossnew, reducing the starting dose cost to just £69.00.

All Wegovy supplied by Cured Pharmacy is sourced directly from UK-licensed wholesalers and manufactured by Novo Nordisk to MHRA standards, guaranteeing you receive genuine medication with proper cold-chain storage throughout the supply process. As a GPhC-registered pharmacy (9012511), we operate under strict regulatory oversight, and every prescription is reviewed by our superintendent pharmacist Tarun Kumar (GPhC 2233073) before dispensing. Your wegovy starting dose requires completion of a free online clinical assessment—typically under three minutes—which is reviewed by a UK-registered prescriber who will determine your suitability for treatment based on your medical history, current medications, and weight loss goals.

How to Administer Your Wegovy Starting Dose Correctly

Proper administration technique for your wegovy starting dose ensures optimal medication absorption and minimises injection site reactions [1]. Wegovy is administered subcutaneously—into the fatty tissue just beneath your skin—using the pre-filled FlexTouch pen device that comes with your starting dose prescription. The three recommended injection sites are your abdomen (at least 5cm away from your belly button), your thigh (front or outer portion), or the back of your upper arm, and you should rotate between these sites each week to prevent lipodystrophy.

To administer your wegovy starting dose, first remove the pen from refrigerated storage and allow it to reach room temperature for approximately 30 minutes, as cold injections can be more uncomfortable. Attach a new pen needle (provided with your prescription), dial the dose selector to 0.25mg—this will be pre-set for starting dose pens—and perform an airflow check as detailed in the patient information leaflet. Clean your chosen injection site with an alcohol wipe, pinch the skin gently, insert the needle at a 90-degree angle, and press the dose button fully until it clicks and the dose counter returns to zero, then hold for six seconds before withdrawing.

Your wegovy starting dose should be administered on the same day each week—choose a day that fits your schedule, as consistency improves treatment adherence and helps maintain stable semaglutide levels [3]. If you miss a dose and it's been less than five days since your scheduled injection day, administer the missed dose as soon as you remember, then resume your normal weekly schedule. If more than five days have passed, skip that dose entirely and take your next scheduled dose on your regular day to avoid taking two doses too close together, which increases side effect risk even at the starting dose level.

Storing Your Wegovy Starting Dose Properly

Wegovy must be stored in a refrigerator between 2°C and 8°C before first use, and the starting dose pen can be kept at room temperature (below 30°C) for up to 28 days once in use [1]. Never freeze Wegovy—if the medication has been frozen, it must be discarded as freezing damages the semaglutide protein structure. Store your pen with the cap on to protect from light, and keep it out of reach of children. Our pharmacy ships Wegovy in temperature-controlled packaging with cool packs to maintain proper storage conditions during transit.

Expected Weight Loss Results from the Wegovy Starting Dose Phase

During the wegovy starting dose month at 0.25mg weekly, patients typically experience modest initial weight loss averaging 1-2kg, though this varies considerably based on individual factors including starting weight, dietary habits, and metabolic response to semaglutide [2]. It's essential to understand that the starting dose is not designed to produce maximum weight loss—its primary purpose is physiological adaptation to allow safe escalation to the therapeutic 2.4mg maintenance dose where the most substantial weight reduction occurs.

Clinical trial data from the STEP programme demonstrated that the majority of weight loss with Wegovy occurs between months 3-8 of treatment, after patients have completed the starting dose titration and reached higher dose levels [2]. In the landmark STEP 1 trial, participants achieved an average weight loss of 14.9% of their initial body weight over 68 weeks, but this result reflects the cumulative effect of the full dose escalation and maintenance at 2.4mg weekly, not the starting dose alone.

Some patients feel discouraged by limited weight loss during the wegovy starting dose phase, but this expectation misunderstands the treatment protocol's design. The 0.25mg starting dose initiates the metabolic and appetite-regulating effects of semaglutide whilst your body builds tolerance—think of it as laying the physiological foundation for the substantial weight loss that occurs at higher doses. Patients who complete the full five-month titration schedule and reach the 2.4mg maintenance dose experience significantly greater long-term weight loss success compared to those who discontinue early due to unrealistic expectations during the starting phase [3]. Our clinical team at Cured Pharmacy provides ongoing support and realistic goal-setting throughout your treatment journey, helping you understand what to expect at each stage from the wegovy starting dose through to maintenance therapy.

Scientific References

1. Novo Nordisk. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy (semaglutide): Patient Information Leaflet. MHRA. [accessed 15 August 2026]
5. General Pharmaceutical Council. (2024). Registered Pharmacies: Cured Pharmacy (Registration 9012511). GPhC Register. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.